MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

Search

Geron Corp

Closed

SectorHealthcare

1.4 3.7

Overview

Share price change

24h

Current

Min

1.31

Max

1.4

Key metrics

By Trading Economics

Income

1.1M

-25M

Sales

19M

48M

EPS

-0.036

Profit margin

-53.331

Employees

229

EBITDA

12M

-16M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+214.81% upside

Dividends

By Dow Jones

Next Earnings

7 May 2025

Market Stats

By TradingEconomics

Market Cap

-875M

860M

Previous open

-2.3

Previous close

1.4

News Sentiment

By Acuity

84%

16%

368 / 382 Healthcare

Geron Corp Chart

Past performance is not a reliable indicator of future results.

Related News

7 Jun 2024, 10:19 UTC

Major Market Movers

Geron Shares Rise Premarket on FDA Nod for Rytelo

Peer Comparison

Price change

Geron Corp Forecast

Price Target

By TipRanks

214.81% upside

12 Months Forecast

Average 4.25 USD  214.81%

High 7 USD

Low 2 USD

Based on 9 Wall Street analysts offering 12 month price targets forGeron Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

7

Buy

2

Hold

0

Sell

Sentiment

By Acuity

368 / 382 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.